Aoki M.,Meiji Seika Kaisha Ltd. |
Okudaira K.,Toho University |
Haga M.,Tokyo University of Science |
Nishigaki R.,Toho University |
Hayashi M.,Tokyo University of Pharmacy and Life Science
Drug Metabolism and Disposition | Year: 2010
The contribution of the lung to drug metabolism was investigated in rats and the possibility of prediction of in vivo metabolism from in vitro studies using rat pulmonary microsomes was assessed. Lidocaine, midazolam, or nifedipine was administered to rats at a dose of 10 mg/kg by the intra-arterial, intravenous, and intraportal routes. The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 ± 0.5, 18.3 ± 0.7, and 12.3 ± 0.3%, respectively. The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 ± 3.3, 52.6 ± 0.4, and 13.5 ± 0.2%, respectively. These results showed that both the liver and the lung contributed to the metabolism of these drugs. The above in vivo pulmonary extraction ratios correlated with the in vitro intrinsic clearance values, which were corrected with the protein unbound ratio in microsomes and plasma, suggesting that pulmonary extraction ratios can be predicted quantitatively from in vitro data. The pulmonary intrinsic clearance values of lidocaine, midazolam, and nifedipine in rat microsomes were lower than their hepatic intrinsic clearance, showing that there was an organ difference in metabolism between the liver and lung. Our results support the importance of the estimation of pulmonary metabolism to predict the total clearance more accurately. Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics. Source
Symphogen and Meiji Seika Kaisha Ltd. | Date: 2011-02-18
Meiji Seika Kaisha Ltd. | Date: 2010-01-20
-Amyrin, a precursor in biosynthesis of soyasapogenol B, is biosynthesized by cyclization of 2,3-oxidosqualene which is generated by the mevalonate pathway, and soyasapogenol B is biosynthesized by two hydroxylations of -amyrin. However, a gene of 22-hydroxylase involved in the sequence of reactions has not been identified. The present inventors identified a gene encoding the hydroxylase for oleanene triterpenes at C-22, and found that oleanene triterpenes could be hydroxylated at C-22 by co-expressing this gene together with one or more specific genes. Further, the present inventors found that soyasapogenol B could be efficiently produced in large quantities by co-expressing this gene for 22-hydroxylase with a gene for 24-hydroxylase.
Meiji Seika Kaisha Ltd. | Date: 2010-08-02
The present invention provides a composition for beverage use comprising an acidic soluble protein, and one or two or more powdery or granular salts selected from the group consisting of alkali metal salts of organic acids and water-soluble basic salts, wherein at least the acidic soluble protein is granulated. Furthermore, the present invention provides a process for producing a composition for beverage use containing an acidic soluble protein, comprising: adding to the acidic soluble protein one or two or more powdery or granular salts selected from alkali metal salts of organic acids and water-soluble basic salts in a proportion of 0.01 to 10 parts by weight with respect to 100 parts by weight of the acidic soluble protein, and subjecting at least the acidic soluble protein to granulation. In the composition for beverage use, the formation of undissolved lumps when the composition is dissolved in water is suppressed.
Meiji Seika Kaisha Ltd. and Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Date: 2013-07-12
A caprazene compound is provided which is the compound represented by the following formula (Ia): wherein Me stands for methyl group, and A is a hydrogen atom, and wherein said compound has the